Combination therapy studies with the vascular disruptive agent combretastatin-a4-phosphate (CA4P)
CA4P leads to rapid vascular shutdown of tumour core, with minimal effects at the well perfused periphery. CA4P showed minimal anti-tumour activity in single agent phase I studies. This thesis examined the feasibility of CA4P combination therapy, examining the hypothesis that two agents may be addit...
| Main Author: | |
|---|---|
| Published: |
University College London (University of London)
2009
|
| Subjects: | |
| Online Access: | http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.564598 |